The global auto-injector market is expected to reach USD 5,713.2 million by 2025 and will grow to USD 23,314.9 million by 2035 at a CAGR of 8.2%. In 2024 revenue of Auto-Injectors was approximately ...

CROSSJECT’s ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors ...

Kaléo's epinephrine auto-injector is associated with lower rates of anaphylaxis-related inpatient hospitalizations compared to other epinephrine auto-injectors Richmond, Virginia, May 15 ...

The prefilled syringe formulation is the first DHE auto-injector that patients can self-administer in a ready-to-use form, according to Amneal. The injector does not require refrigeration ...

Brekiya is now the first DHE auto-injector to be approved by the regulator The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ Brekiya (dihydroergotamine mesylate) injection ...

1.256). The study was presented as a poster titled "AUVI-Q (epinephrine, USP) vs. Other Epinephrine Auto-Injector Prescription Was Associated with Reduced Inpatient Hospitalizations for ...

They represent a strategic investment in bolstering the nation’s security infrastructure, especially as the EOD-CBRN Unit remains critical in combating terrorism and other emerging security ...

JPL CBRND EB’s data-focused programs support JPEO-CBRND’s ability to protect the joint force, understand the threat, mitigate the effects of a CBRN event, and accelerate CBRN defense ...

Manufacturers are also investing in the development of high-quality materials tailored for large-volume auto-injectors and wearable drug delivery systems. These innovations cater to the increasing ...

The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday.